Sana's Funding Stretches to Mid-2027 as Diabetes Cell Therapy Nears Human Testing

Sana Biotechnology ended the third quarter of 2026 with $121.7M in cash, a sum the company says will cover operations into mid-2027. The figures came with its results on 5 November. The disclosure sets a relatively near-term window in which the company would need to show progress or raise further capital, although the material reviewed gave no detail on spending plans or financing intentions.

The biggest pipeline item is SC451, a hypoimmune islet cell therapy derived from induced pluripotent stem cells (iPSCs) and aimed at type 1 diabetes. Sana says it could file an investigational new drug (IND) application and start a Phase 1/2 trial as early as this year. No trial design, dose, site or enrolment details were available.

A second programme follows. Sana expects to begin a clinical study of SG293 in non-Hodgkin lymphoma in the first quarter of 2027. That would put two programmes in human testing within a few months of each other, if timelines hold.

Sana also cited a letter in the New England Journal of Medicine reporting 14-month islet data for UP421, and said its collaboration with the Mayo Clinic is moving forward. The material reviewed did not include the underlying results or the terms of the Mayo arrangement.

For context, an IND application permits a sponsor to begin human trials of an investigational product in the US. Under the FDA process, a study can generally proceed once a 30-day review period ends without a clinical hold.